The purpose of this meta-analysis was to evaluate the efficacy and safety of celecoxib, a
selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy …

Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung
cancer. In non-small cell lung cancer (NSCLC), COX-2 is overexpressed in most …

Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …

7337 Background: Cyclooxigenase-2 (COX-2) is overexpressed in about 70% of NSCLC.
Selective inhibitors of COX-2 have antitumor activity by blocking angiogenesis and …

Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …

PURPOSE:: To assess the overall and progression-free survival, response rate, and toxicity
of combined docetaxel and celecoxib in the treatment of patients with non-small cell lung …

Overexpression of cyclooxygenase-2 (COX-2) is frequently presentin lung cancer and may
play a significant role in carcinogenesis, invasion, and metastasis. It has been associated …

Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …

AIM OF THE STUDY: The primary purpose of this study is to investigate if pretreatment
plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of …

Purpose Trials combining irinotecan/docetaxel and irinotecan/gemcitabine in second-line
treatment of non–small-cell lung cancer (NSCLC) have yielded promising results …